Enanta Pharmaceuticals opened lower at $11.55, compared with its previous close of $11.60. In the last trading session, the stock traded between $11.06 and $11.64. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Enanta Pharmaceuticals is now worth
$ 12.29
Resulting in a loss of
$ 87.71 (87.71%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.42 (-3.63%)
Day High
$11.64
Day Low
$11.06
Day Open
$11.55
Prev Close
$11.60
Volume
2,16,754
1W Return
4.87%
1M Return
-9.11%
3M Return
-17.47%
6M Return
-27.69%
1Y Return
-7.15%
Market Cap ($ Mn)
326
PE Ratio
-
PB Ratio
3.92
PEG Ratio
-
ROE
-85.63%
ROCE
-30.81%
EPS (TTM)
$-0.67
1 Week
4.87%
1 Month
-9.11%
3 Months
-17.47%
6 Months
-27.69%
9 Months
-21.55%
Enanta to present zelicapavir RSV data at IDWeek 2026
Enanta Pharmaceuticals will present data for zelicapavir at IDWeek 2026. Zelicapavir is an oral, once-daily N-protein inhibitor for RSV treatment. The conference runs from October 21 to October 24, 2026. Events are held virtually and at the Walter E. Washington Convention Center.
1mo agoEnanta Pharmaceuticals to present at two investor conferences in September
Enanta Pharmaceuticals will participate in two investor conferences in September 2026. Management will present a fireside chat at the Baird 2026 Global Healthcare Conference on September 15, 2026 at 1:25 p.m. ET. A second fireside chat is scheduled at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026 at 8:00 a.m. ET. Live webcasts and replays, archived for at least 30 days, will be available on Enanta's investor relations website. Enanta's pipeline spans RSV treatments in virology and inflammatory disease programs targeting KIT, STAT6, and MRGPRX2 inhibition.
2mo agoEnanta Pharma reports $19.5 million Q3 loss, advances RSV pipeline
Enanta Pharmaceuticals posted a $19.5 million net loss for the quarter ended June 30, 2026, as revenue dropped 21% year-over-year to $14.4 million. Despite the miss on estimates, the company highlighted progress in its RSV pipeline, including the start of the LOTUS pediatric trial and upcoming RESOLVE adult trial. With $211.5 million in cash, Enanta maintains a runway into fiscal 2029.
3mo agoEnanta Pharmaceuticals enters open market sale agreement with Jefferies
Enanta Pharmaceuticals entered an agreement with Jefferies to sell up to $75M of common stock. The sales will be conducted at market prices through the agent. Proceeds are intended for general corporate purposes.
4mo agoHC Wainwright reiterates Buy rating on Enanta Pharma
HC Wainwright & Co. analyst Brandon Folkes has reiterated a Buy rating on Enanta Pharma (NASDAQ: ENTA) with a maintained price target of $20.
4mo agoEnanta advances zelicapavir into registrational Phase 2b/3 trial
Enanta Pharmaceuticals is advancing zelicapavir into a registrational Phase 2b/3 clinical trial for high-risk adults with RSV in 4Q 2026, following a successful FDA meeting, with topline data expected in 2027.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Enanta Pharmaceuticals is now worth
$ 12.29
Resulting in a loss of
$ 87.71 (87.71%)
Note: Past profits do not guarantee future returns.
